Rate My Professor Josh Davis

Professor Josh Davis holds the position of Professor in the School of Medicine and Public Health within the College of Health, Medicine and Wellbeing at the University of Newcastle, Australia. His academic background includes a Bachelor of Medicine and Bachelor of Surgery with Honours (MBBS Hons) from the University of Sydney, Diploma in Tropical Medicine and Hygiene (DTM&H), Fellowship of the Royal Australasian College of Physicians (FRACP), Graduate Certificate in Population Health (Grad Cert PopHealth), and a PhD from Charles Darwin University completed in 2011. He currently serves as Senior Staff Specialist in Infectious Diseases and general medicine at John Hunter Hospital, Newcastle, and Senior Principal Research Fellow at the Menzies School of Health Research and Charles Darwin University. Previously, from 2006 to 2012, he was Senior Staff Specialist in Infectious Diseases at Royal Darwin Hospital.

Professor Davis's research specializations focus on clinical trials in severe infectious diseases, including management of Staphylococcus aureus bloodstream infections, bone and joint infections, severe sepsis, viral hepatitis, Aboriginal health, and adaptive platform trials such as Bayesian designs. He has authored over 220 peer-reviewed publications, garnering more than 14,300 citations with an h-index of 51. Key publications include "Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management" (Clinical Microbiology Reviews, 2015) and "Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial" (Clinical Infectious Diseases, 2016). His achievements include the NHMRC Research Excellence Award for the top-ranked CDF2 application nationally (2019), the Fenner Award for Advanced Research in Infectious Diseases (2021) from the Australasian Society for Infectious Diseases (past president), and chief investigator roles on NHMRC/MRFF grants exceeding $52 million. As founding director and current deputy director of the HMRI Infection Research Program, and leader of trials like SNAP for S. aureus infections and ROADMAP for prosthetic joint infections, he has significantly impacted the field through innovative clinical research and trial design.